Comment on

• Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates.

  Kempton CL, Soucie JM, Abshire TC. Kempton CL, et al. J Thromb Haemost. 2006 Dec;4(12):2576-81. doi: 10.1111/j.1538-7836.2006.02233.x. Epub 2006 Sep 26. J Thromb Haemost. 2006. PMID: 17002659
• Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.

  Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knöfler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Göttl U. Iorio A, et al. J Thromb Haemost. 2010 Jun;8(6):1256-65. doi: 10.1111/j.1538-7836.2010.03823.x. Epub 2010 Mar 17. J Thromb Haemost. 2010. PMID: 20345722
• Concentrate-related inhibitor risk: is a difference always real?

  Iorio A, Marcucci M, Makris M. Iorio A, et al. J Thromb Haemost. 2011 Nov;9(11):2176-9. doi: 10.1111/j.1538-7836.2011.04480.x. J Thromb Haemost. 2011. PMID: 21854537 No abstract available.
• Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII.

  Aledort LM, Navickis RJ, Wilkes MM. Aledort LM, et al. J Thromb Haemost. 2011 Nov;9(11):2325-7. doi: 10.1111/j.1538-7836.2011.04496.x. J Thromb Haemost. 2011. PMID: 21880112 No abstract available.